This therapeutic approach holds promising clinical significance, since studies have proved that Carotuximab is safe and effective in the clinical treatment of glioma [45, 46] and blocking TGFβ pathway in astrocytes holds promise for treating AD [62, 65]. Here, TGFB1 is linked to central nervous system cancer.